Related Experiment Video
Updated: Mar 29, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Trabectedin for the treatment of breast cancer
Maurizio D'Incalci1, Alberto Zambelli2
1a Department of Oncology , IRCCS - Istituto di Ricerche Farmacologiche Mario Negri , Via La Masa 19, Milan 20156 , Italy.
Introduction:
Trabectedin is an anti-tumor compound registered in Europe and in several other countries, for the second-line treatment of soft tissue sarcoma (STS) and for ovarian cancer in combination with liposomal doxorubicin. Trabectedin inhibits cancer cell proliferation mainly affecting the transcription regulation. Trabectedin also acts as a modulator of tumor microenvironment by reducing the number of tumor associated macrophages (TAM). Because of its unique mechanism of action, trabectedin has the potential to act as antineoplastic agent also in several solid malignancies, including breast cancer (BC).
Areas Covered:
This article reviews the preclinical and clinical data of trabectedin focusing on development in metastatic BC (mBC). Comments regarding the nature and the results of these trials are included.
Expert Opinion:
Trabectedin is thought to have a crucial activity with defective DNA-repair machinery and also in modulating the tumor micro-environment and the immune-system of cancer patients. From the current available data, we recognize a potential activity of trabectedin in mBC and support the renewed efforts to better elucidate the value of trabectedin in this indication.
Insights
Trabectedin shows potential as an anti-cancer drug for metastatic breast cancer (mBC) by affecting transcription and the tumor microenvironment. Further research is needed to confirm its value in treating mBC.
Area of Science:
- Oncology
- Pharmacology
Background:
- Trabectedin is an approved anti-tumor agent for soft tissue sarcoma and ovarian cancer.
- It inhibits cancer cell proliferation by regulating transcription and modulates the tumor microenvironment by reducing tumor-associated macrophages (TAMs).
Purpose of the Study:
- To review preclinical and clinical data on trabectedin's development in metastatic breast cancer (mBC).
Main Methods:
- Review of existing preclinical and clinical trial data.
- Analysis of trabectedin's efficacy and mechanism of action in mBC.
Main Results:
- Trabectedin exhibits potential activity in mBC, possibly due to its effects on DNA repair and tumor microenvironment modulation.
- The drug's unique mechanism suggests broader applicability in solid malignancies.
Conclusions:
- Trabectedin demonstrates potential in mBC, warranting further investigation.
- Its activity in defective DNA-repair machinery and immune modulation supports its role in cancer therapy.
More Related Videos
13:43Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models
Published on: April 1, 2022
10:13Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment
Published on: June 21, 2022
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Drugs that Stabilize Microtubules
Drugs that Destabilize Microtubules